Servier collaborates in the treatment of pancreatic cancer
Servier and Oncodesign Precision Medicine (OPM) announce a collaborative research agreement, named ‘STarT Pancreas’, to identify and validate new therapeutic targets in Pancreatic Ductal Adenocarcinoma.
The three-year agreement between Oncodesign Precision Medicine (OPM) and Servier includes two steps: Co-construction of an AI analytical platform based on data generated in the OncoSNIPE clinical trial® and identification of targets with this platform; then experimental validation of the pre-selected targets.
Dr. Walid S. Kamoun, Servier’s Director of R&D Oncology: “We are delighted to initiate this collaboration with OPM, and to contribute to the development of an AI-based data analysis solution that could enable us to identify new therapeutic targets in pancreatic ductal adenocarcinoma, a dreaded cancer increasing in industrialized countries. This partnership is in line with the Group’s strategy of making the fight against cancer one of its strategic priorities, targeting hard-to-treat cancers for which treatment options are limited.”
Pancreatic cancer is considered as one of the most difficult cancers to treat, due to its insidious symptoms and high degree of malignancy leading to a high mortality rate.
Did you know?
Servier and Oncodesign are also engaged in a research collaboration in Parkinson’s disease since 2019.